SCHEDULE: Perceptive Advisors Boosts Aldeyra Stake to 8.7%

Perceptive Advisors and its affiliates reported a beneficial ownership of 8.7% in Aldeyra Therapeutics, Inc., holding 5,222,311 common shares.

Summary

• Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") beneficially own 5,222,311 shares of Aldeyra Therapeutics, Inc. common stock.
• This represents 8.7% of the outstanding common stock of Aldeyra Therapeutics, Inc.
• The ownership percentage is calculated based on 60,162,773 shares outstanding as of November 4, 2025, as reported in the Issuer's Form 10-Q filed on November 5, 2025.
• The Master Fund directly holds these shares, with Perceptive Advisors serving as its investment manager, and Joseph Edelman as the managing member of Perceptive Advisors.
• All Reporting Persons share both voting and dispositive power over the 5,222,311 shares.
• The filing certifies that the shares were not acquired for the purpose of changing or influencing control of the issuer, except for activities related to nominations under Rule 14a-11.

Sentiment

Score: 7

Explanation: The filing indicates a significant beneficial ownership stake by Perceptive Advisors, a well-regarded life sciences investment firm. This can be interpreted as a positive signal of confidence in Aldeyra Therapeutics by a sophisticated institutional investor.

Positives

• A significant stake (8.7%) held by a specialized life sciences investment firm like Perceptive Advisors may signal confidence in Aldeyra Therapeutics' long-term prospects.
• The continued holding or increase in stake by a sophisticated institutional investor can be viewed positively by other investors.

Negatives

• This filing does not disclose any negative operational or financial information about Aldeyra Therapeutics. It is a disclosure of beneficial ownership.

Risks

• This Schedule 13G filing does not detail specific operational or financial risks related to Aldeyra Therapeutics. It is a disclosure of beneficial ownership by an institutional investor.

Future Outlook

This Schedule 13G filing does not contain forward-looking statements or guidance regarding Aldeyra Therapeutics, Inc.'s future operations or financial performance, as it is a disclosure of beneficial ownership.

Management Comments

• This filing does not contain direct quotes or paraphrased statements from Aldeyra Therapeutics' management. It includes certifications from Joseph Edelman as Managing Member of Perceptive Advisors LLC and Perceptive Life Sciences Master Fund, Ltd.

Industry Context

Perceptive Advisors is a prominent investment firm specializing in the life sciences sector. Their significant stake in Aldeyra Therapeutics, a biotechnology company, indicates continued interest and potential belief in the company's pipeline or market position within the broader pharmaceutical and biotech industry. Such institutional ownership is common in the biotech sector, where specialized funds often take substantial positions in companies with promising drug candidates.

Comparison to Industry Standards

• Perceptive Advisors is a well-known hedge fund focused on the life sciences, often taking significant stakes in emerging biotech companies. Their 8.7% stake in Aldeyra Therapeutics is a substantial position, aligning with their strategy of concentrated investments in companies they believe have strong potential.
• For a biotech company like Aldeyra, having a specialized institutional investor with a significant stake can be seen as a vote of confidence, potentially attracting other institutional investors.
• The ownership percentage is within the typical range for institutional investors seeking influence or a substantial return in smaller to mid-cap biotech firms, without necessarily seeking outright control.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a substantial stake may instill confidence and potentially influence other investors' perceptions of the company's value and prospects.
• Company Management: Awareness of a large, specialized investor holding a significant stake may influence strategic decisions, though the filing states the investment is passive.

Next Steps

• This filing does not outline any specific future actions, events, or milestones for Aldeyra Therapeutics or the Reporting Persons beyond the ongoing beneficial ownership.

Key Dates

Recommendation

The filing indicates a significant, passive ownership stake by a specialized life sciences investment firm. While this signals institutional confidence, it does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and await further operational updates or financial results from Aldeyra Therapeutics to make a more informed decision, while acknowledging the positive signal from this institutional backing.

Keywords

Aldeyra Therapeutics, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals, ALD